问题从来不是是否普遍提高风险收入分成。而是哪些合同、提高多少，以及预期会流失哪些客户。 数字健康公司面对的版本并非通用问题。结果风险的签署速度快于公司能否承担的判断——12个月测量窗口对11个月销售周期——因此忽略风险收入分成的答案必然出错。分析必须从参与率和毛利率而非收入起步。
问题从来不是是否普遍提高风险收入分成。而是哪些合同、提高多少，以及预期会流失哪些客户。 数字健康公司面对的版本并非通用问题。结果风险的签署速度快于公司能否承担的判断——12个月测量窗口对11个月销售周期——因此忽略风险收入分成的答案必然出错。分析必须从参与率和毛利率而非收入起步。
调整风险收入分成是任何数字健康业务中最快的杠杆。不需要新增注册成员、无需招聘、无需新产品，且下一期PMPM账单即可到账。运营者却最不愿触碰，因此结果风险定价过低远比过高常见。
有用的价格分析不会给出一个数字。它给出分段：哪些合同的参与率能支撑更高风险分成，哪些已达归因结果的上限，以及风险分成分布显示条款由销售对话而非政策决定。
不舒服之处在于，一次有效调整会刻意增加客户流失。若调整后未流失任何合同，说明风险分成提高幅度太小。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 多数合同以报价风险分成成交，几乎无谈判。
✓ 类似合同的风险分成差异很大，由单次销售讨论而非统一规则决定。
✓ 风险分成保持不变，而毛利率在多个12个月测量窗口内持续下降。
通常会让情况更糟的做法。 对整个合同簿统一提高风险分成，导致低参与合同流失，却仍在可支撑更高条款的合同上留下利润空间。
It is for you if you run or finance a digital health company and almost every deal closes, and closes quickly. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Convert 180 existing employer relationships into $11.7M incremental outcomes-contingent revenue by Month 24 without new-plan procurement.
The leak it closes. $6.5M device leakage reduced by shifting kit cost to employer opt-in, improving gross margin 7 points on employer cohort
The assumption it rests on. 180 employers accept outcomes-contingent terms at 45% at-risk share — the engine put the probability at 0.7.
| Investment required | $0.6–0.9M total (2 FTE employer specialists @ $180K fully loaded each × 18 months + $120K enablement tools) |
| Expected return | 13.0× on $0.9M investment ($11.7M incremental revenue by Month 24) |
| Revenue, year 1 | $3.9M incremental employer outcomes revenue |
| Revenue, year 2 | $11.7M cumulative incremental employer outcomes revenue |
| Revenue, year 3 | $18.5M cumulative if employer cohort grows 15% YoY |
| Exit criteria | Terminate move if employer conversion rate <25% by Month 12 OR if employer at-risk share demanded exceeds 50% OR if device-kit leakage reduction <10 points by Month 18. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 定价与收入优化, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
没有通用答案，有用的分析按分段进行。能说的是，你担心的流失通常集中在改善后反而对公司有利的群体。
先对新客户更稳妥但更慢；现有客户才是钱所在。合理顺序是先调整新客户定价，观察一个季度成交率，再在续约时通知现有客户上调。
那你就是在用价格以外的东西竞争，或者并非如此——这才是真正的问题。在成本结构不支持的情况下靠价格竞争，是以越来越大的规模亏损的最可靠方式。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית